CMS hesitates to approvePET for cancer despite data
Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage.
Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage. A CMS advisory panel came to the conclusion that clinical data for nine conditionally approved cancer indications of FDGPET were too ambivalent to support the petition.
The NOPR team suggested that making decisions case by case would be counterproductive. They remain optimistic that CMS will look favorably at the latest findings before making a final coverage decision, which is scheduled for January.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
